Acasti Pharma Inc. Welcomes Professor Jacques Genest to Its Scientific Advisory Board
08 July 2010 - 10:30PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma Inc.
("Acasti") are pleased to announce the expansion of Acasti's
Scientific Advisory Board (SAB) by welcoming Pr. Jacques Genest,
MD, CM; FRCP(C); FACC; FAHA, to join Pr. Steven Nissen (Cleveland
Clinic), Pr. Ruth McPherson, MD, PhD, Pr. William Harris (Sandford
Research/USD), Pr. Thomas G. Hartman (Rutgers University Center),
and Dr. Magdy M. Abdel-Malik (Quaestio Global Partners).
Dr. Jacques Genest is a Professor of Medicine and Head of
Cardiology at McGill University Health Centre. His research
focuses on the metabolic and genetic basis of premature coronary
artery disease and the role of high density lipoproteins ("HDL") in
atherosclerosis. His team has contributed to the
identification of several genes involved in the metabolism of HDL,
including the ABCA1 gene as the molecular cause of Tangier disease.
His research is supported by a number of prestigious grants
from agencies including the Canadian Institutes of Health Research
("CIHR"), the Heart and Stroke Foundation of Canada, the National
Institutes of Health ("NIH") in the United States and the March of
Dimes. He has been involved in designing and running several
large clinical trials (HOPE-2, homocysteine; the JUPITER trial),
sits on several pharmaceutical companies' advisory boards and is a
reviewer for many scientific journals and granting agencies.
For the past 15 years, he has participated in the elaboration of
Canadian Cardiovascular Society/ Canadian guidelines for the
diagnosis and treatment of dyslipidemia and prevention of
cardiovascular disease.
"Acasti continues to demonstrate its commitment to excellence by
welcoming Dr. Jacques Genest, one of the most distinguished
cardiologists in Canada," said Dr. Farhad Amiri, Senior
Associate-Director, Preclinical Studies, R&D of Acasti.
"We are privileged to have the opportunity to work with Dr. Genest
and benefit from his guidance through our path to clinical efficacy
studies," he added.
"It is an extremely important achievement for Acasti to have
someone of the caliber of Dr. Genest join our SAB, adding another
valuable asset to the team. Dr. Genest decided to join us
after discussing Acasti's lead drug candidate's structure, safety,
and efficacy. While getting ready to embark into Acasti's
initial clinical evaluation of the drug candidate (CaPre™), we feel
privileged to benefit from Dr. Genest's valuable knowledge in lipid
management relative to high density lipoproteins (HDL) and coronary
artery disease," said Dr. Tina Sampalis, President of Acasti Pharma
Inc. "Dr. Genest is a world renowned expert in unraveling the
pathophysiology of dyslipidemia and translating this knowledge in
the clinical realm," she added.
Dr. Genest is strongly committed to promoting healthy lifestyles
for the prevention of chronic diseases, including atherosclerosis.
The role of nutrition in promoting and maintaining health
cannot be over-emphasized.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The
Company sponsors clinical trials aimed to demonstrate its product
health benefits and to obtain regulatory approval for label health
claims. Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory
approvals. Neptune's products are marketed and distributed in
over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize
the polyunsaturated omega-3 fatty acids EPA and DHA, which have
been shown to have substantial health benefits and which are
stabilized by potent antioxidants. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular conditions
within the over-the-counter, medical food and prescription drug
markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development
of a prescription drug candidate is currently in progress.
Advanced clinical development and commercialization is planned to
be carried out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or
implied by such forward-looking statements. In addition
to statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements
labeled with the terms "believes," "belief," "expects," "intends,"
"anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed
with the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, Vice-President, Finance & Administration
450-687-2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
450-686-4555 (x403)
t.sampalis@acastipharma.com
www.acastipharma.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024